Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.75 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Celgene, Lilly, Sirtex, and Taiho Oncology, Inc.
Saturday, April 23, 2016
Grand Hyatt New York
New York, NY
There is a need for specialized education for clinicians who manage some of the most difficult-to-treat forms of gastrointestinal cancers. The School of Gastrointestinal Oncology™ (SOGO™) will provide a multi-module curriculum-based program focused exclusively on gastrointestinal tumors’ management. This intensive 1-day interactive program will provide a comprehensive review of data on the most important aspects related to the multidisciplinary management of gastrointestinal tumors. The program will focus on the latest data on prognostic and predictive markers that impact clinical decision-making, current and emerging treatment strategies, and case-based lectures by expert faculty whose will focus on the practical application of knowledge to the complex care scenarios encountered in contemporary practice settings.
Best Practices in Sequencing Lines of Treatment in Metastatic Colorectal Cancer With or Without an Actionable Marker
Novel Targeted Approaches in Hepatocellular Carcinoma
A Changing Paradigm: The Potential of Immunotherapy in GI Cancers
To Transplant or Not to Transplant: That Is the Question
This educational program is directed toward oncologists and gastroenterologists whose primary practice focus is gastrointestinal (GI) cancers and who intend to reinforce their knowledge base and expand their expertise in GI diagnosis, risk stratification, personalization of care, and best practices for multidisciplinary communication. Participants will be primarily oncologists, surgeons, gastroenterologists, interventional radiologists, radiation oncologists, fellows and other professionals who treat GI cancers whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of GI cancers.
At the conclusion of this activity, participants should be better prepared to:
Describe current and evolving patient and tumor information that can be used to stratify risk and inform clinical decision-making in the management of gastrointestinal malignancies.
Assess landmark clinical trial findings and apply them to changing clinical practice paradigms to personalize care and optimize outcomes.
Delineate effective strategies to proactively mitigate and manage predictable side effects related to the management of gastrointestinal malignancies so that treatment outcomes can be maximized.
Discuss emerging clinical trial findings on novel compounds and strategies to manage gastrointestinal malignancies.
Apply emerging clinical trial data to manage cases in the context of evolving treatment paradigms for gastrointestinal tumors.
John Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Director, Ruesch Center for the Cure of GI Cancers
Michael A Choti, MD, MBA, FACS
Professor and Chair
Department of Surgery
UT Southwestern Medical Center
You must be logged in to PER to register for this meeting